PepVax Inc. (New York, NY)

https://www.pepvax.co/

Speratum has licensed PepVax’s SMARTMid technology, a fully synthetic method for producing nucleic acid molecules that aligns with Speratum’s own technologies. Together, Speratum and PepVax have launched a collaborative research project parallel, in preparation for future combinatory preclinical and clinical trials.